Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Author(s): Eyal C. Attar and Karen K. Ballen

Volume 2, Issue 3, 2006

Page: [199 - 209] Pages: 11

DOI: 10.2174/157339406777934708

Price: $65

conference banner
Abstract

Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.

Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy